ErlySign, a promising health tech startup focused on the early detection of oral cancer, has successfully raised Rs 16 crore ($1.8 million) in its pre-Series A funding round. The round was led by renowned investor Ashish Kacholia. This investment will play a crucial role in advancing the startup’s mission to bring its groundbreaking oral cancer detection kit to market.
Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign has developed innovative solutions aimed at identifying oral cancer at its earliest stages. The company’s flagship offering is India’s first salivary biomarker-based test, which can detect pre-cancerous conditions long before visible symptoms appear. This innovative technology promises to revolutionize the way oral cancer is diagnosed, significantly improving early detection and treatment outcomes.
With the newly acquired funding, ErlySign plans to conduct rigorous clinical trials and secure crucial approvals from the Central Drugs Standard Control Organisation (CDSCO) to ensure the product’s safety and efficacy. The startup’s ultimate goal is to provide accessible, affordable, and accurate cancer screening solutions for millions of people, thereby reducing mortality rates through early intervention.
Looking forward, ErlySign plans to expand its reach with the introduction of CRISPR miRNA-based testing technology. This new approach will allow the detection of multiple types of cancer using a single saliva sample, delivering results in just 15–20 minutes. This could pave the way for a major shift in the landscape of cancer detection, making it faster and more efficient than ever before.
ErlySign’s ambitious vision and innovative approach make it a key player in the healthtech sector, poised to make a lasting impact on the fight against cancer.
